APRE

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aprea Therapeutics Inc revenue for the last quarter amounts to 1.85K USD, decreased -99.48 % YoY.

Aprea Therapeutics Inc. EPS for the last quarter amounts to -0.47 USD, decreased -26.56 % YoY.

Aprea Therapeutics Inc (APRE) has 8 emplpoyees as of December 15 2025.

Today APRE has the market capitalization of 8.88M USD.